034runner: Acquisition is a very, very big factor almost everyone involved with Tapimmune has gone that route, they have not assembled this team without a game plan.
There is not one Big Pharma out there that cannot utilize their technology, now that have licenced the her2/neu and are working on the triple negative people are beginning to make the correlation between the two.
Stock has been consolidating as it has moved up, I believe that selling has been one of our investors shaving their position, to exercise their .40 warrants.
Remember you all have just come to the party, but TPIV is very undervalued at these prices, don't worry about the crumbs here at .40, .60 or even .75 as there is a hero sandwich in the oven.
News 
Market Data 
Discover 
AI
